Kairos Pharma reports ENV-105 plus apalutamide median PFS of 17.7 months vs 2 months in Phase 2 mCRPC trial (P=0.0008)

Kairos Pharma, LTD.

Interim Phase 2 analysis showed a statistically significant PFS difference for ENV-105 plus apalutamide vs apalutamide alone (median 17.7 vs 2 months; P=0.0008).
Kairos modified the Phase 2 protocol to enroll patients earlier, after PSA increase on an androgen signaling inhibitor, randomized to enzalutamide alone or with ENV-105.
The company targets completion of the Phase 2 trial in or before Q4 2027; CEO John Yu called the interim results an important clinical signal for ENV-105.
Patients were enrolled at Cedars-Sinai Medical Center, City of Hope and Huntsman Cancer Institute at the University of Utah.
ENV-105 (carotuximab) targets CD105, which Kairos describes as a key driver of resistance and relapse after standard cancer therapy.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.